Tuberculosis Drug Discovery & Development
The Gordon Research Conference on Tuberculosis Drug Development was formed for the purpose of bringing together scientists at the cutting edge of tuberculosis (TB) drug discovery and development from academia and the pharmaceutical industry to discuss new advances in this rapidly developing and expanding field of research. The inaugural GRC on Tuberculosis Drug Development was held in 2001 at Colby-Sawyer College in New Hampshire and was chaired by Clifton E. Barry III. The introduction of this GRC in 2001 coincided with the marked upturn of interest in TB drug discovery and development globally, in both the public and private sectors, which followed a period of almost four decades of inactivity in this field. The second conference, chaired by Ken Duncan, was held at Queen’s College in Oxford in 2003, and the third, chaired by James Sacchettini, took place in 2005 at the University of New England in Maine.
What is a GRC? Gordon Research Conferences (GRC) are 5-day meetings that bring scientists together from around the world to present and discuss unpublished research with other leaders in their field.
This Gordon Research Conference (GRC) series is related to the "Tuberculosis Drug Discovery & Development" Gordon Research Seminar (GRS)
series. Although a related GRS will typically be scheduled in conjunction with its parent GRC each time it meets, that may not always be the case. Refer to the individual meetings in the Meeting History
section below for more details. For more information about the associated Gordon Research Seminar (GRS) series, click here
.What is a GRS? Gordon Research Seminars (GRS) are 2-day meetings that bring graduate students and post-docs together to discuss their cutting edge research among peers and mentors. Each GRS immediately precedes an associated Gordon Research Conference (GRC), and topics addressed at the GRS relate closely to the GRC.